Comparison of HER-2/neu with histological grade and hormone (ER, PR) status in carcinoma breast

Purva Sharma; Deepak Bali; Hemant Kumar Singh; Alok Mohan

doi:10.53730/ijhs.v6nS4.11246

Authors

Purva Sharma Assistant Professor, Department of Pathology, NCR Institute of Medical Sciences, Meerut
Deepak Bali
deepakbali23@gmail.com
Assistant Professor, Department of General Surgery, NCR Institute of Medical Sciences, Meerut
Hemant Kumar Singh Professor cum Statistician, Department of Community Medicine, NCR Institute of Medical Sciences, Meerut
Alok Mohan Professor, Department of Community Medicine, NCR Institute of Medical Sciences, Meerut

Keywords:

HER-2/neu, estrogen receptors, progesterone receptors, carcinoma breast, NPI

Abstract

Objectives :- The study was performed with the aim to compare HER-2/neu over expression with age, size of tumor, histopathological type, grade of tumor, lymph node positivity, NPI, and hormone receptors ER and PR. Methods :- The study was conducted on 66 cases of breast carcinoma. All the cases underwent immunohistochemistry for ER, PR and HER-2/neu over expression. HER-2/neu over expression was compared with prognostic factors. Results :- The age range of these patients was from 30-70 years with mean age of 49.92 years. HER-2/neu was strongly positive (score 3) in 12/66 ( 18.18%), moderate or equivocal ( score 2) in 7 /66 (10.60 %) and mild ( score 1) in 16/66 (24.24%) and it was negative ( score 0) in 31/66 (46.97 %). Estrogen Receptor ( ER) was positive in 38/66 (57.57%) cases, progesterone receptors (PR) was positive in 30/66 (45.45%) cases. Triple negative cases were 16/66 (24.24%) and triple receptor positive cases were 04/66 (6.06%).

Downloads

Download data is not yet available.

References

Ali EM, Ahmed R.HA; Ali MA Correlation of breast cancer subtypes based on ER PR, and HER-2 expression with axillary lymph node status cancer and oncology research. 2014, Vol. 2 : 51-57.

Almasri NM, Al Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res 2005;7:R598-604

Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, et al. Correlation of HER-2 over-expression with clinicopathological parameters in Tunisian breast carcinoma. World J Surgical Oncol 2008;6:112-119.

Azam M, Qureshi A, Mansoor S. Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma. J Pak Med Assoc. 2009;59:736-40.

Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009;2:444-55

Carter D, Schmitt SJ and Millis RR. The breast In Sternberg's diagnostic surgical pathology. Stacey E. Millis (Editor) 5th ed. Wolters Kluwer, Lippincott, Williams Wilkins, 2010 Vol. I pg. 285.

Chand P, Garg A, Singla V, Rani N. Evaluation of immunohistochemical profile of breast cancer for prognostics and therapeutic use. Niger J Surg.2018, 24:100-106.

Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005;23:7721-35.

Descotes F, Pavy J-J, Adessi GL. Human breast cancer: Correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Research 1993.13;119-124.

Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999;17:1442-8. 38.

Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-67.

Elston CW and Ellis IO : Assessment of histological grade. In Elston CW and Ellis, IO (eds.), The breast Vol. 13. Churchill Livingstone, Edinburg, New York, 1998, pp. 356-84.

Francis G, Beadle G, Thomas S, Mengersen K, Stein S. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Pathology. 2006;38:391-8.

Haybittle JL, Blamey RW, Elston CW et al. A prognostic index in primary breast cancer. Br. J. Cancer.1982; 45 : 361-366.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong H, Bauerfeind I, Felber M, Wang H, Beryt M, Seshadri R, Hepp H, Slamon DJ. Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer. Journal of the national Cancer Institute. 2003;95(2):142-153.

Kurshumliu F, Luci LG, Kadare S et al. Classification of patients with breast cancer according to Nottingham Prognostic Index highlights significant difference in immunohistochemical marker expression. World Journal of Surgical oncology. 2014; 12 : 243.

Lazennec G, Bresson D, Lucas A, et al: ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology. 2001; 142: 4120-4130.

Lee AK, Rosen PP, DeLellis RA, Saigo PE, Gangi MD, Groshen S, et al. Tumor marker expression in breast carcinomas and relationship to prognosis. An immunohistochemical study. Am J Clin Pathol 1985;84:687-96

Lester SC, Bose S, Chen Yunn-Yi, et al: Protocol for the examination of specimens from patients with invasive carcinoma of the breast. AJCC/UICC TNM 7th edition. CAP 2013.

Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, et al. High prevalence of triple negative tumors in an urban cancer center. Cancer. 2008; 113 : 608-15.

National cancer Registry Programme – population based cancer registries report at http:/www.ncrpindia.org/Reports/PBCR_Rpt_2004 -2005, chapter-6, page68. Accessed non 23/10/2011.

Nikhra P, Patel S, Taviad D, Chaudhary S. Study of ER (estrogen receptor), PR (Progesterone Receptor) and HER-2/NEU (Human epidermal growth factor receptor) expression by immunohistochemistry in breast carcinoma. IJBAR 2014;05:275-8.

Noguchi M, Koyasaki M, Ohta N et al. c-erbB-2 oncoprotein expression versus internal mammary lymph node metastasis as additional prognostic factors in patients with axillary lymph node positive breast cancer. Cancer 1992;69:2953-2960.

Pakseresht S, Ingle GK, Bahadur AK, Ramteke VK, Singh MM, Garg S, et al. Risk factors with breast cancer among women in Delhi. Indian J Cancer 2009;46:132-8.

Prati R, Apple SK, He J, Gornbei JA, Chanh HR. Histopathologic characteristics are predicting HER-2/neu amplification in breast cancer. Breast J. 2005;11:433-9.

Puvitha RD, Shifa S. Breast carcinoma, receptor status, and HER-2/neu over expression revisited. International J. of Scientific study. 2016, Vol. 3, 52-58.

Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007;25:4772-8.

Rashed MM, Ragab M, Galal MK. The association of HER-2/neu over expression in relation to P53 nuclear accumulation, Hormonal receptor status and common Clinio pathological prognostic parameters in a series of Egyptian women with invasive ductal carcinoma. Eur. J. Gen Med, 2007; 4(2) : 73-79.

Ray A, Sharma BK, Kaur S, et al. Over expression of c-erbB2 oncoprotein and associated pathobiological factors in invasive primary breast cancer. Indian J Exp Biol. 2004;42(3):253-8

Reddy P, Mithraa SD. Correlation of ER, PR, HER-2/neu and Ki67 with other prognostic factors in breast carcinoma. Trop J Pathol Microbiol. 2020;6(5):349-361.

Rosai J (Editor), Rosai and Ackerma Surgical pathology 10th Edition Vol. 1. Mossby Elsevier Edinburgh London New York Oxford Philadelphia St. Louis Sydney Tornto, 2011 p. 1659-1770.

Shak S: Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Review. Semin Oncol 4 Suppl. 1999; 12: 71-77.

Stead LA, Lash TL, Sobieraj JE, Chi DD, westrup JL Charlot M et al. Triple negative breast cancer are increased in black women regardless of age or Body Mass Index. Breast cancer Res. 2009; 11 : R18.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Thaib, P. K. P., & Rahaju, A. S. (2022). Clinicopathological profile of clear cell renal cell carcinoma. International Journal of Health & Medical Sciences, 5(1), 91-100. https://doi.org/10.21744/ijhms.v5n1.1846

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. : Efficacy and safety of trastuzumab as a single agent in first line treatment of HER-2/neu overexpressing metastatic breast cancer. J. Clin. Oncol. 2002; 20 : 719-26.

Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev (2008),17,3319-24

Yadav R, Sen R, Chauhan P. ER, PR, HER-2/neu status and relation to clinicopathological factors in breast carcinoma. International Journal of pharmacy and Pharmaceutical Sciences 2016, Vol. 8; 287-290.